Hosted on MSN

Regeneron’s cat and birch allergy mAbs score in Phase III trials

Regeneron Pharmaceuticals’ first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) met their primary endpoints in two Phase III trials in adults with moderate-to-severe cat or ...
Nasdaq

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
Seeking Alpha

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support ...